![Katherine Ruffner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Katherine Ruffner
Keine laufenden Positionen mehr
Profil
Katherine L.
Ruffner worked as a Senior Director of Clinical Development at Seagen Inc. She was the Vice President of Clinical Development at CTI BioPharma Corp from 2008 to 2019.
Prior to that, she was an Assistant Professor at Vanderbilt University from 2002 to 2007.
She also worked as the Vice President of Clinical Development at ALX Oncology Holdings, Inc. from 2020 to 2021 and as the Chief Medical Officer at Cardiff Oncology, Inc. in 2021 to 2022.
Ruffner received her undergraduate degree from Duke University and her graduate degree from the University of Tennessee.
Ehemalige bekannte Positionen von Katherine Ruffner
| Unternehmen | Position | Ende |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.04.2022 |
| ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01.05.2021 |
| CTI BIOPHARMA CORP. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.2007 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Katherine Ruffner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
81
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt University
Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cardiff Oncology, Inc.
 Cardiff Oncology, Inc. Medical SpecialtiesHealth Technology Develops diagnostic products | Health Technology |
University of Tennessee
 University of Tennessee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
